Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results.
Oct 16 (Reuters) — ROCHE HOLDING AG: Fda Approves Roche’s Enspryng, A First-in-class Il-6r Inhibitor, As The First And Only At-home Subcutaneous Treatment Option For Thyroid Eye Disease (Ted) Roche Holding Ag - Enspryng Offers First At-home Subcutaneous Treatment Option For Ted Roche Holding Ag - Fda Approval Based On
FDA approved Roche unit Genentech’s Enspryng for adults with thyroid eye disease. Enspryng becomes the first at-home subcutaneous treatment for the condition, with maintenance dosing every four weeks. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While P
For best results when printing this announcement, please click on link below: FDA Approves Genentech’s Enspryng, a First-in-Class IL-6R Inhibitor, as the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED) FDA approval based on Phase III SatraGO-1 and -2 studies, with SatraGO-2 demonstrat